While monogenic obesity treatments, such as injectable melanocortin-4 receptor (MC4R) agonists, have shown efficacy in addressing mutations like those in leptin receptors (LEPR), such interventions are less applicable to polygenic obesity, which involves numerous variants with small cumulative effects [23]. This evidence concerns the gene MC4R and Obesity.